These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25517988)

  • 1. In Vitro-In Vivo Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler®.
    Weers JG; Clark AR; Rao N; Ung K; Haynes A; Khindri SK; Perry SA; Machineni S; Colthorpe P
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):268-80. PubMed ID: 25517988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seebri Neohaler and Utibron Neohaler for COPD.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):39-41. PubMed ID: 27027687
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro dose comparison of Respimat
    Ciciliani AM; Langguth P; Wachtel H
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1565-1577. PubMed ID: 28603412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
    Prakash A; Babu KS; Morjaria JB
    Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
    Vaidya SS; Khindri S; Maahs S; Machineni S; Hara H; Juan A; Kaiser G
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):285-95. PubMed ID: 27310329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Wei X; Hindle M; Kaviratna A; Huynh BK; Delvadia RR; Sandell D; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):358-371. PubMed ID: 29878859
    [No Abstract]   [Full Text] [Related]  

  • 10. An Exploration of Factors Affecting
    Ruzycki CA; Martin AR; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632
    [No Abstract]   [Full Text] [Related]  

  • 11. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.
    Walenga RL; Longest PW
    J Pharm Sci; 2016 Jan; 105(1):147-59. PubMed ID: 26852850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
    Prescrire Int; 2014 Dec; 23(155):288. PubMed ID: 25629143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined in Vitro-in Silico Approach to Predict Deposition and Pharmacokinetics of Budesonide Dry Powder Inhalers.
    Ruzycki CA; Murphy B; Nathoo H; Finlay WH; Martin AR
    Pharm Res; 2020 Sep; 37(10):209. PubMed ID: 32995953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.
    Leung SS; Tang P; Zhou QT; Tong Z; Leung C; Decharaksa J; Yang R; Chan HK
    AAPS J; 2015 Nov; 17(6):1407-16. PubMed ID: 26201967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers.
    Zhang Y; Gilbertson K; Finlay WH
    J Aerosol Med; 2007; 20(3):227-35. PubMed ID: 17894531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance Comparisons of Jet and Mesh Nebulizers Using Different Interfaces in Simulated Spontaneously Breathing Adults and Children.
    Ari A; de Andrade AD; Sheard M; AlHamad B; Fink JB
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):281-9. PubMed ID: 25493535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
    Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
    Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dry powder inhaler with reduced mouth-throat deposition.
    Wang ZL; Grgic B; Finlay WH
    J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.